Citations

Clear

2117 citation(s) found for "Mayo, Steven".

p53 Mutations in Carcinoma of the Esophagus and Gastroesophageal Junction
Sengpiel, Christina, König, Inke R. , Rades, Dirk , Noack, F. , Duchrow, M., Schild, Steven E. , Ludwig, D, Homann, Nils, Schild, Steven

Mayo Clinic

Cancer Investigation | January 21, 2009 | Volume: 27 | Issue: 1 | Pages: 96-104

10.1080/07357900802161047 | PMID 19160092 Get It

Health Behavior Insights—The Transtheoretical/ Stages of Change Model: Carlo C. DiClemente, PhD
Werch, Chudley E., Ames, Steven C. , Moore, Michele , Thombs, Dennis L., Hart, Andrea R.

Mayo Clinic

Health Promotion Practice | December 30, 2008 | Volume: 10 | Issue: 1 | Pages: 41-48

10.1177/1524839908323519 | PMID 19116432 Get It

Showcased in this article is an interview with Carlo C. DiClemente, PhD, an internationally renowned health behavior researcher and codeveloper of the Transtheoretical or Stages of Change Model. In this verbatim interview transcript, later edited by the authors and interviewee, Dr. DiClemente, he provides practical information and frank commentary on the steps to follow and pitfalls to avoid in developing, implementing, evaluating, and disseminating efficacious programs for affecting the health and well-being of individuals and populations. A concluding section summarizes key lessons learned from the professional experiences of Dr. DiClemente and discusses implications for advancing health behavior intervention practice and research.
Change in Perceived Stress, Partner Support, Decisional Balance, and Self-Efficacy Following Residential Nicotine Dependence Treatment
Ames, Steven C. , Croghan, Ivana T. , Clark, Matthew M. , Stevens, Susanna R., Schroeder, Darrell R. , Eberman, Kay M., Hurt, R. Douglas , Patten, Christi A. , Hays, J. Taylor , Schroeder, Darrell

Mayo Clinic

Journal of Addictive Diseases | December 30, 2008 | Volume: 27 | Issue: 1 | Pages: 73-82

10.1300/j069v27n01_08 | PMID 18551890 Get It

Psychosocial Factors Associated with an Increased Frequency of Prostate Cancer Screening in Men Ages 40 to 79 Years: The Olmsted County Study
Wallner, Lauren P. , Sarma, Aruna V. , Lieber, Michael M., Sauver, Jennifer L. St. , Jacobson, Debra J., McGree, Michaela E. , Gowan, Monica E., Jacobsen, Steven J. , St Sauver, Jennifer L

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 8, 2008 | Volume: 17 | Issue: 12 | Pages: 3588-3592

10.1158/1055-9965.epi-08-0050 | PMID 19064575 Get It

Abstract Prostate cancer is the second leading cause of cancer deaths among U.S. men. Early detection is associated with drastically improved 5-year survival rates. It is unclear, however, what psychosocial factors motivate or discourage men from taking advantage of both prostate-specific antigen (PSA) testing and digital rectal examination (DRE). The goal of the current study was to identify psychosocial factors that influence screening behavior for prostate cancer in a cohort of 2,447 men. In 1990, a randomly selected cohort of Caucasian men, ages 40 to 79 years, from Olmsted County, Minnesota, were enrolled in the study. These men completed a questionnaire containing queries on family history of prostate cancer, concern about getting prostate cancer, and marital status. Medical and laboratory records were reviewed to determine the number DREs (1989-1996) and PSA tests (1989-1998). Frequent screening was defined as the upper 25th percentile for number of DREs (>4) or PSAs (>3). Men who have a family history and men who worry or have concern about prostate cancer were more likely [odds ratio (OR), 1.5; 95% confidence interval (95% CI), 1.2-2.0 and OR, 1.9; 95% CI, 1.4-2.5] to seek screening compared with those without a family history or worry. The association between family history and frequent screening was similar in men who were married or living with someone (OR, 1.7; 95% CI, 1.2-2.2); however, it was reduced among men who live alone (OR, 0.6; 95% CI, 0.2-1.8). These data suggest that psychosocial factors such as family history, worry, or concern about prostate cancer and marital status may play an important role in men's decisions about prostate cancer screening. (Cancer Epidemiol Biomarkers Prev 2008;17(12):3588–92)
Age, Obesity, and Medical Visits in Family Medicine
Rohrer, James E. , Takahashi, Paul Y. , Adamson, Steven C., Takahashi, Paul

Mayo Clinic

Population Health Management | October 17, 2008 | Volume: 11 | Issue: 5 | Pages: 255-259

10.1089/pop.2008.0005 | PMID 18942917 Get It

The purpose of this study was to assess whether the relationship between obesity and use of medical visits is different for geriatric patients than for other adults. A retrospective analysis was conducted using medical records drawn from a large group practice in Rochester, Minnesota. Adult patients ( n = 1715) were sorted into 2 groups (frequent visitors and others). Separate multiple logistic regression models were estimated for geriatric and non-geriatric patients. Patients who were 65 years of age or older with moderate comorbidity had elevated odds of being frequent visitors (odds ratio [OR] = 6.13, confidence interval [CI] = 3.27–11.49), compared to patients with no comorbidity. Body mass index (BMI), gender, and marital status were unrelated to visit frequency in the geriatric group. Younger patients with a BMI ≥ 35 kg/m 2 had greater odds of being frequent visitors compared to patients with normal body mass, after adjusting for comorbidity, age, marital status, and gender (OR = 1.96, CI = 1.31–2.92). ORs also were significantly greater for subjects with low (OR = 2.13, CI = 1.51–3.01) and moderate comorbidity (OR = 3.32, CI = 2.32–4.76) versus no comorbidity. In our sample of family medicine patients who were referred to specialists, BMI ≥ 35 kg/m 2 is an independent risk factor for frequent utilization of medical visits among adults who are younger than age 65, but not among geriatric patients. Comorbidity is strongly related to visit frequency among both older and younger adult patients. (Population Health Management 2008;11:255–259)
The Associations Between Serum Sex Hormones, Erectile Function, and Sex Drive: The Olmsted County Study of Urinary Symptoms and Health Status Among Men
Gades, Naomi M. , Jacobson, Debra J., McGree, Michaela E. , Sauver, Jennifer L. St. , Lieber, Michael M., Nehra, Ajay, Klee, George G., Jacobsen, Steven J. , Girman, Cynthia J. , St Sauver, Jennifer L

Mayo Clinic

The Journal of Sexual Medicine | October 11, 2008 | Volume: 5 | Issue: 9 | Pages: 2209-2220

10.1111/j.1743-6109.2008.00924.x | PMID 18624959 Get It

ABSTRACT Introduction Testosterone replacement therapy has been used in the treatment of sexual dysfunction; however, its use remains controversial, and the effectiveness and long-term health implications are unknown. Aim To evaluate the association between sex hormone serum levels, erectile function, and sexual drive in a population-based sample of men. Methods A stratified random sample of men residing in Olmsted County, Minnesota, completed a questionnaire containing questions from the Brief Male Sexual Function Inventory (BMSFI), and participated in a clinical exam, which included serum hormone measurements. Main Outcome Measures Levels of sexual drive (libido) and erectile function as assessed by the BMSFI and serum testosterone, bioavailable testosterone, and estradiol measurements. Results Out of 414 men, 294 had a regular sexual partner and androgen measurements at the 14th year of follow-up. Total testosterone and erectile function were significantly correlated even after adjustment for age (r = 0.12, P = 0.04). Conversely, total testosterone was not significantly correlated with sex drive (r = 0.08, P = 0.17). Bioavailable testosterone was significantly correlated with both erectile function and sex drive (r = 0.16, P = 0.01 and r = 0.20, P = 0.001, respectively). However, these associations disappeared after age adjustment (r = 0.04 and r = 0.09). Conclusions These cross-sectional results suggest the relationship between sex hormones and sexual function is complex, and that the age-related decline in sexual function may be due to age-related declines in levels of bioavailable testosterone rather than total testosterone levels.
Chemotherapy for Colorectal Cancer Liver Metastases
Wagman, Lawrence D., Alberts, Steven R.

Mayo Clinic

The Oncologist | October 6, 2008 | Volume: 13 | Issue: 10 | Pages: 1063-1073

10.1634/theoncologist.2008-0142 | PMID 18838438 Get It

Abstract Learning Objectives After completing this course, the reader should be able to: Explain the role of chemotherapy in the treatment of liver metastases from colorectal cancer and the shifting goals of therapy—from palliation to prolongation of life.Select among the evolving treatment options for patients with unresectable, not optimally resectable, and resectable liver metastases.Discuss the unresolved research issues, including the optimal timing of perioperative chemotherapy and the role of biologic agents in the management of liver metastases from colorectal cancer. CME This article is available for continuing medical education credit at CME.TheOncologist.com Colorectal cancer (CRC) is a highly prevalent malignant disease in industrialized nations. The annual incidence of invasive CRC in the U.S. is among the highest in the world, and the liver is the only metastatic site in approximately one third of patients. Without treatment, patients with metastatic disease have a poor prognosis; however, long-term survival benefits and even cure have been reported in patients undergoing surgical resection of metastases. In addition, advances in chemotherapy, imaging, and surgical techniques have increased the proportion of patients who are eligible for resection. Combination therapy with fluorouracil and leucovorin has been the mainstay of treatment for metastatic CRC; however, the introduction of newer agents, such as oxaliplatin and irinotecan, and targeted agents, such as cetuximab and bevacizumab, has yielded improvements in response rates (RRs) and survival. Maximizing the exposure of hepatic metastases to high target concentrations of cytotoxic drugs using hepatic arterial infusion (HAI) increases RRs further than with systemic chemotherapy; however, the impact of HAI on survival is unclear. As the goals of chemotherapeutic treatment for metastatic CRC increasingly shift from palliation to prolongation of survival, improvement in RRs, and downsizing of tumors in order to enable or optimize resection, treatment in a multidisciplinary environment involving a medical oncologist, radiologist, and surgical oncologist with hepatobiliary expertise will become central to deciding the best course of therapy and timing of surgery.
Improving Diabetes Care in Practice
Peterson, Kevin , O’Connor, Patrick J. , Nyman, John A. , Prineas, Ronald J. , Smith, Steven A., Arneson, Thomas J., Corbett, Victor A., Weinhandl, Joyce C., Lange, Carol J., Hannan, Peter J., Radosevich, David M. , Corbett, V, Peterson, Kevin J.

Mayo Clinic

Diabetes Care | September 22, 2008 | Volume: 31 | Issue: 12 | Pages: 2238-2243

10.2337/dc08-2034 | PMID 18809622 Get It

OBJECTIVE—The purpose of this study was to determine whether implementation of a multicomponent organizational intervention can produce significant change in diabetes care and outcomes in community primary care practices. RESEARCH DESIGN AND METHODS—This was a group-randomized, controlled clinical trial evaluating the practical effectiveness of a multicomponent intervention (TRANSLATE) in 24 practices. The intervention included implementation of an electronic diabetes registry, visit reminders, and patient-specific physician alerts. A site coordinator facilitated previsit planning and a monthly review of performance with a local physician champion. The principle outcomes were the percentage of patients achieving target values for the composite of systolic blood pressure (SBP) <130 mmHg, LDL cholesterol <100 mg/dl, and A1C <7.0% at baseline and 12 months. Six process measures were also followed. RESULTS—Over 24 months, 69,965 visits from 8,405 adult patients with type 2 diabetes were recorded from 238 health care providers in 24 practices from 17 health systems. Diabetes process measures increased significantly more in intervention than in control practices, giving net increases as follows: foot examinations 35.0% (P < 0.0.001); annual eye examinations 25.9% (P < 0.001); renal testing 28.5% (P < 0.001); A1C testing 8.1%(P < 0.001); blood pressure monitoring 3.5% (P = 0.05); and LDL testing 8.6% (P < 0.001). Mean A1C adjusted for age, sex, and comorbidity decreased significantly in intervention practices (P < 0.02). At 12 months, intervention practices had significantly greater improvement in achieving recommended clinical values for SBP, A1C, and LDL than control clinics (P = 0.002). CONCLUSIONS—Introduction of a multicomponent organizational intervention in the primary care setting significantly increases the percentage of type 2 diabetic patients achieving recommended clinical outcomes.
Limited stair-climbing ability and weight control in family medicine patients
Rohrer, James E. , Barnes, Darryl E. , Adamson, Steven C., Altrichter, Paul M., Yapuncich, Victor P.

Mayo Clinic

Chronic Illness | September 16, 2008 | Volume: 4 | Issue: 3 | Pages: 183-187

10.1177/1742395308089060 | PMID 18796507 Get It

Objective: To assess the association between self-assessed stair-climbing limitation and weight control among family medicine patients, after adjustment for age, gender, marital status, body mass index (BMI), and co-morbidity. Methods: This study was a retrospective analysis of a cohort of 840 adult family medicine patient records drawn from a large family medicine department in Rochester, Minnesota. Weight control was measured as no change or decline in BMI over approximately 1 year. Results: Adjusting for co-morbidity and other confounders using multiple logistic regression analysis revealed that limited stair-climbing ability was unrelated to weight control over approximately 1 year. Instead, patients with BMI ≥ 30 were more likely to control their weight (p<0.01), and age exhibited a non-linear relationship with weight control. The odds of weight control were lower for patients between the ages of 36 and 45 years than for those aged 18—35 years (p<0.01). Conclusions: In our sample of family medicine patients, self-assessed stair-climbing limitations did not preclude weight control. Weight gain prevention programmes might be targeted at patients who are entering middle age.
WOUND-HEALING PROPERTIES OF TRANSFORMING GROWTH FACTOR β (TGF-β) INDUCIBLE EARLY GENE 1 (TIEG1) KNOCKOUT MICE
Taguchi, Manabu, Moran, Steven L. , Zobitz, Mark E., Zhao, Chunfeng , Subramaniam, Malayannan , Spelsberg, Thomas C., Amadio, Peter C.

Mayo Clinic

Journal of Musculoskeletal Research | September 15, 2008 | Volume: 11 | Issue: 02 | Pages: 63-69

10.1142/s0218957708002012 | PMID 20016760 Get It

Transforming growth factor beta (TGF-β) has a broad effect on wound healing, but many questions remain about the regulation of TGF-β during the healing process. TGF-β inducible early gene 1 (TIEG1) is a primary response gene for TGF-β that controls the activities of the TGF-β/Smad pathway, the primary TGF-β signaling pathway. The purpose of this study was to investigate the role of TIEG1 in cutaneous wound healing using TIEG1 knockout mice. The wound healing in TIEG1 knockout mice and wild-type controls was evaluated by wound breaking strength, Western blot, and histology at postoperative days 3, 7, and 14. Although re-epithelialization of both groups was similarly complete at day 7, the TIEG1 knockout mice had a significantly lower wound breaking strength than the controls at postoperative day 14. These results suggest that TIEG1 expression may be an important factor involved in the initiation and support of normal cutaneous wound healing.